Tuesday, June 10, 2025

 

Mice can recognize an artificial limb as their own



Animal model of forelimb embodiment could be used to develop better neuroprostheses




PLOS

Mice can recognize an artificial limb as their own 

image: 

The rubber-hand illusion was translated to the mouse model. Just like in humans, embodiment in mice can be achieved by brushing the real forelimb of the mouse and the artificial limb (yellow) in synchrony to generate matching visual and touch percepts.

view more 

Credit: Luc Estebanez (CC-BY 4.0, https://creativecommons.org/licenses/by/4.0/)





Mice can develop a sense of embodiment of an artificial limb, similar to humans who participate in the rubber-hand illusion experiment, according to a study published June 5th in the open-access journal PLOS Biology by Luc Estebanez from CNRS: Centre National de la Recherche Scientifique, France, and colleagues.

We perceive our limbs as part of ourselves, and we feel threatened by any menace to them. This sense of embodiment can be disrupted by brain injuries leading to a loss of recognition of body parts, and even to their active rejection from the body representation. In the case of amputated patients, efficient use of a prosthesis can be hampered by a lack of prosthesis embodiment, thereby causing a progressive decrease in daily prosthesis use and finally an abandonment of the prosthetic limb. In contrast, prosthesis embodiment is associated with a reduction in the sensations arising from the phantom of the missing limb, including painful perceptions.

In an experimental setting, it is possible to either build or disrupt the sense of embodiment of an artificial limb by manipulating the temporal coincidence of tactile and visual stimulations. In particular, in the rubber-hand illusion experiment, a rubber limb is placed in a position that makes it visible to the participant, while the real hand is hidden from view. Both the hidden real hand and the visible artificial hand are stroked in synchrony with a brush. A large fraction of the subjects in these experiments report that after this stimulation, the rubber hand they are seeing is their real hand. So far, the physiological bases of sensory-based forelimb embodiment remain unclear, partly due to the lack of an animal model to study embodiment.

To address this challenge, Estebanez and colleagues developed an analog of the rubber-hand illusion embodiment protocol for mice. The researchers presented head-fixed mice with an artificial, 3D-printed static replica of their right forelimb at a plausible physiological location. At the same time, their real forelimb was hidden from sight and held in place below the platform where the artificial limb was located. During a two-minute pairing sequence, the researchers applied mechanically-controlled synchronous or asynchronous brush strokes to the real and the artificial forelimbs. Then the researchers dropped a sharp object toward the artificial forelimb that was within view of the animal.

During this sequence, the gaze of the mice was tracked with high-speed videography. Consistent with the broader literature on the rubber-hand illusion, the mice focused their gaze on the threat for several seconds when brush strokes were synchronous, but not when they were asynchronous. The behavioral response was also stronger when the artificial forelimb looked similar to a limb versus a white cube-shaped object.

According to the authors, this work has practical implications for the study of forelimb embodiment in a model that offers unparalleled experimental venues. For example, mapping out the brain circuits of embodiment using genetic and optogenetic research tools could lead to novel embodiment restoration strategies. Beyond this, the research also supports the idea that rodents can display behavioral correlates of embodiment in settings that are known to trigger embodiment in humans. This adds to a series of recent findings suggesting that rodents, and mice in particular, can display some capabilities that have been associated with higher cognitive functions.

The authors add, “The rubber hand illusion is a staple of the study of body representation in humans, but so far there was no equivalent of this test in the most actionable model: mice. Here we have shown that limb embodiment can be triggered and measured efficiently in mice. This opens up many opportunities to better understand the basic mechanisms of body ownership and apply it for instance to improve prosthetics.”


In your coverage, please use this URL to provide access to the freely available paper in PLOS Biologyhttps://plos.io/3Ft1HUi

Citation: Hayatou Z, Wang H, Chaillet A, Shulz DE, Ego-Stengel V, Estebanez L (2025) Embodiment of an artificial limb in mice. PLoS Biol 23(6): e3003186. https://doi.org/10.1371/journal.pbio.3003186

Author countries: France, China

Funding: This work was funded by LE PRC Hermin, ANR. https://anr.fr/ to LE, JCJC Mesobrain, ANR. https://anr.fr/ to LE, PRC Expect, ANR. https://anr.fr/ to DES, PRC PerBaCo, ANR. https://anr.fr/ to DES, Fondation 3DS https://www.lafondation3ds.org/fr/ to LE, 80|Prime 2020, CNRS, https://www.cnrs.fr/ to LE and AC, MITI PRIME 2024, CNRS, https://www.cnrs.fr/ to LE and AC, PRC MotorSense, ANR. https://anr.fr/ to VE, RISE iNavigate, 873178, Horizon 2020 Framework Programme. https://cordis.europa.eu/project/id/873178 to DES, OI hCODE, Université Paris-Saclay, https://www.universite-paris-saclay.fr/objets-interdisciplinaires/h-code to LE. The funders played no role in the design of the study, data collection and analysis, preparation of the manuscript, or decision du publish.

 

Personality disorder pioneer reveals half-century journey transforming psychiatric classification



Former American Psychiatric Assocition (APA) President John Oldham reflects on reshaping personality disorder diagnosis from rigid categories to dimensional understanding



Genomic Press

John M. Oldham, MD, MS 

image: 

John M. Oldham, MD, MS, Baylor College of Medicine, USA.

view more 

Credit: John M. Oldham, MD, MS





NEW YORK, New York, USA, 10 June 2025 -- In a comprehensive Genomic Press Interview published today in Brain Medicine, John M. Oldham, MD, MS, one of psychiatry's most influential architects of personality disorder theory, traces his remarkable journey from frontier medicine roots in Oklahoma to revolutionizing how mental health professionals understand and diagnose personality pathology.

Transforming Diagnostic Paradigms

Dr. Oldham's contributions have fundamentally reshaped personality disorder classification, moving the field from rigid diagnostic categories toward a more nuanced dimensional system. As former President of both the American Psychiatric Association and the International Society for the Study of Personality Disorders, he and a team of colleagues spearheaded the development of the Alternative DSM-5 Model for Personality Disorders (AMPD), marking what many consider the most significant epistemological shift in psychiatric diagnosis for these conditions in decades.

"The dimensional approach more accurately reflects the gradations and interplay of personality traits we see in clinical practice," Dr. Oldham explains in the interview. His innovative New Personality Self-Portrait online assessment tool (npsp25.com), based on a book continuously in print for 35 years, has provided both clinicians and the public with accessible ways to understand personality styles and potential pathology.

From Bedside to Policy Leadership

Dr. Oldham's career trajectory exemplifies the integration of clinical expertise with systems-level innovation. After training at Columbia, including psychoanalytic study under Otto Kernberg, he participated in the development of one of the first semi-structured clinical research interviews for DSM-III personality disorders, the Personality Disorders Examination (PDE). This groundbreaking work emerged during his tenure at Cornell, where he served as chief of an inpatient unit specializing in intensive treatment.

"My training took place when the Vietnam War was winding down. I was fortunate to enroll in the Berry Plan, which allowed me to complete my specialty training before assuming active duty," Dr. Oldham reflects. His two years of military service as a Major in the US Air Force, including interviews with returning POWs who had endured solitary confinement for up to 7 years, provided early lessons in resilience and crisis response that would prove invaluable throughout his career.

His leadership extended beyond academic medicine when he accepted the role of Chief Medical Officer for the New York State Office of Mental Health, a position he held from 1988 to 2002. In this capacity, he served as the senior physician in a large public system that, when he first assumed the role, operated approximately 25,000 inpatient beds.  He emphasized bridging the gap between the state hospital centers and academic education, fostering formal teaching partnerships between the hospitals and medical school psychiatry departments. . Following the September 11, 2001 (9/11) attacks, Dr. Oldham helped navigate that unprecedented mental health crisis with what colleagues describe as exceptional clarity and resolve.

Advancing Scientific Understanding Through Collaboration

Throughout his career, Dr. Oldham has demonstrated how collaborative research can advance understanding of complex psychiatric conditions. As co-Principal Investigator of the New York site for the Collaborative Longitudinal Personality Disorders Study (CLPS), he contributed to generating crucial findings about personality disorder trajectories over more than a decade. This ambitious NIMH-funded project represented one of the most comprehensive investigations into personality pathology ever undertaken.

Questions remain about how dimensional approaches to personality disorders will be implemented in routine clinical practice. How will training programs need to adapt to teach these new  diagnostic frameworks? What implications does this shift have for treatment planning and insurance coverage? These considerations highlight ongoing challenges as the field transitions from traditional categorical thinking.

Editorial Excellence and Mentorship

Currently serving as editor or co-editor for three major journals, Journal of Psychiatric PracticeJournal of Personality Disorders, and Borderline Personality Disorder and Emotion Dysregulation, Dr. Oldham continues to shape scientific discourse in the field. His editorial work emphasizes pragmatic, evidence-informed approaches to complex psychopathology while fostering the next generation of researchers and clinicians. "My family values have always made me conscientious and a good team player. The best leader is the leader who listens," Dr. Oldham shares, reflecting on the leadership principles that have guided his editorial work.

The interview reveals personal insights that illuminate Dr. Oldham's professional philosophy. His early life, in a family culture that emphasized concern and respect for others, profoundly influenced his approach to patient care, particularly his later focus on helping individuals with serious medical illnesses cope with psychological distress. This humanistic perspective permeates his scientific contributions, from developing assessment tools to advocating for improved treatment access.

Legacy and Future Directions

Dr. Oldham's work raises intriguing questions about the future of psychiatric diagnosis. As genetic and neurobiological research advances, how will dimensional models of personality integrate with emerging biomarkers? What role will technology play in implementing these more sophisticated diagnostic approaches in clinical settings? His contributions provide a foundation for addressing these challenges while maintaining focus on improving patient outcomes.

The evolution from categorical to dimensional understanding of personality disorders represents more than a technical advancement, it reflects a fundamental shift in how psychiatry conceptualizes human psychological variation. This transformation promises more personalized treatment approaches but also demands new frameworks for clinical training and practice guidelines.

Dr. John M. Oldham's Genomic Press interview is part of a larger series called Innovators & Ideas that highlights the people behind today's most influential scientific breakthroughs. Each interview in the series offers a blend of cutting-edge research and personal reflections, providing readers with a comprehensive view of the scientists shaping the future. By combining a focus on professional achievements with personal insights, this interview style invites a richer narrative that both engages and educates readers. This format provides an ideal starting point for profiles that explore the scientist's impact on the field, while also touching on broader human themes. More information on the research leaders and rising stars featured in our Innovators & Ideas – Genomic Press Interview series can be found in our publications website: https://genomicpress.kglmeridian.com/.

The Genomic Press Interview in Brain Medicine titled "John M. Oldham: Personality styles and personality disorders, a dimensional framework," is freely available via Open Access on 10 June 2025 in Brain Medicine at the following hyperlink: https://doi.org/10.61373/bm025k.0059.

About Brain MedicineBrain Medicine (ISSN: 2997-2639, online and 2997-2647, print) is a peer-reviewed medical research journal published by Genomic Press, New York. Brain Medicine is a new home for the cross-disciplinary pathway from innovation in fundamental neuroscience to translational initiatives in brain medicine. The journal's scope includes the underlying science, causes, outcomes, treatments, and societal impact of brain disorders, across all clinical disciplines and their interface.

Visit the Genomic Press Virtual Library: https://issues.genomicpress.com/bookcase/gtvov/

Our full website is at: https://genomicpress.kglmeridian.com/

 

Italian neuroscientist links childhood trauma to lifelong brain consequences



Sara Poletti's research reveals how early adversity triggers lasting neurobiological changes through immune dysregulation




Genomic Press

Sara Poletti, PhD 

image: 

Sara Poletti, PhD, Ospedale San Raffaele.

view more 

Credit: Sara Poletti, PhD





MILAN, Italy, 10 June 2025 -- In a revealing Genomic Press Interview published today in Brain Medicine, Sara Poletti, PhD, senior researcher at IRCCS Ospedale San Raffaele Milan, illuminates the profound connections between childhood adversity and lifelong vulnerability to psychiatric disorders through persistent neuroinflammation pathways and alterations in brain structure.

Bridging Psychology and Neurobiology

Dr. Poletti's groundbreaking research has transformed understanding of how early life experiences become biologically embedded, creating lasting changes in brain structure and immune function. As the only tenure-track psychologist in psychiatry at her institute, she has pioneered multidisciplinary approaches that combine neuroimaging, genetic analysis, and immunological markers to decode the biological signatures of childhood trauma.

"The immune system doesn't just fight infections—it plays a crucial role in shaping our mental health throughout life," Dr. Poletti explains. "Childhood trauma can fundamentally reprogram these immune responses, creating vulnerability to depression, bipolar disorder, and other psychiatric conditions decades later."

Her work raises critical questions about prevention and intervention: Can we identify biological markers of trauma early enough to prevent psychiatric disorders? How do protective factors buffer against neuroinflammatory responses? What role does timing play in trauma's biological impact? These questions drive Dr. Poletti's innovative research program.

From Microscope to Mind: An Unexpected Journey

Dr. Poletti's path to neuroscience began with a childhood microscope and evolved through encounters with Freud's writings and neuroimaging studies of violent criminals. This eclectic background equipped her with unique perspectives on brain-behavior relationships. Despite warnings that psychedelic and inflammation research was "career suicide" in 2006, she persisted in exploring these then-marginalized areas that have since become central to psychiatric research.

As Project Leader at San Raffaele's Psychiatry and Clinical Psychobiology Unit, Dr. Poletti coordinates diverse teams of psychologists, physicians, and biologists. Her leadership of a European Research Area Network (ERA-NET) Neuron project on the consequences of infections on mental health exemplifies her ability to foster international collaboration in advancing inflammation's role in psychiatric disorders.

Transforming Challenges into Opportunities

One defining moment in Dr. Poletti's career came when she reluctantly accepted a teaching position in human physiology—a field she knew little about. "It required extensive studying and put me to the test," she recalls. "However, I learned a great deal from this experience, both scientifically and personally." This challenge deepened her understanding of body-brain interactions, proving invaluable for her later research on neuroinflammation.

Her resilience in facing academic challenges mirrors the resilience she studies in trauma survivors. Some individuals exposed to severe childhood adversity develop psychiatric disorders while others don't—understanding these differences could revolutionize preventive psychiatry. What biological factors confer resilience? How can we enhance natural protective mechanisms? Dr. Poletti's research addresses these fundamental questions.

Clinical Implications and Future Directions

Dr. Poletti's findings have immediate clinical relevance. By identifying specific inflammatory markers associated with childhood trauma, her work provides potential targets for novel interventions. This precision medicine approach could transform psychiatric treatment from symptom management to addressing underlying biological mechanisms. Following this line of reasoning she published the first paper on the use of an immunomodulatory agent (interleukin 2) to treat mood disorders.

"I aim to further elucidate the role of the immune system and its interaction with the environment in psychiatric disorders," Dr. Poletti states. Her vision includes developing prevention strategies to reduce mental illness odds, particularly for individuals with trauma histories. This preventive focus represents a paradigm shift from reactive to proactive psychiatric care.

Mountain Peaks and Scientific Summits

The interview reveals how Dr. Poletti's passion for Italian mountain hiking informs her scientific approach. Standing atop Sasso Nero at 2,847 meters, she finds the clarity and renewal that fuel her research endeavors. This connection to nature reflects her holistic view of mental health, recognizing that human wellbeing extends beyond biological mechanisms to encompass environmental and experiential factors.

Questions about trauma's transgenerational effects add another dimension to Dr. Poletti's work. Can childhood trauma alter genetic expression in ways that affect offspring? How do social and cultural factors modulate biological responses to adversity? These considerations expand the scope of trauma research from individual to societal levels.

Advancing Global Mental Health

Dr. Poletti's research contributes to a growing recognition that mental health is inseparable from physical health, particularly immune function. This integrated perspective challenges traditional boundaries between psychiatry and other medical specialties, promoting more comprehensive approaches to patient care.

The implications extend beyond individual treatment. If childhood trauma creates lasting biological vulnerabilities, what responsibilities do societies have for preventing adverse childhood experiences? How can healthcare systems better integrate trauma screening and early intervention? Dr. Poletti's work provides scientific grounding for these critical policy discussions.

Dr. Sara Poletti's Genomic Press interview is part of a larger series called Innovators & Ideas that highlights the people behind today's most influential scientific breakthroughs. Each interview in the series offers a blend of cutting-edge research and personal reflections, providing readers with a comprehensive view of the scientists shaping the future. By combining a focus on professional achievements with personal insights, this interview style invites a richer narrative that both engages and educates readers. This format provides an ideal starting point for profiles that explore the scientist's impact on the field, while also touching on broader human themes. More information on the research leaders and rising stars featured in our Innovators & Ideas – Genomic Press Interview series can be found in our publications website: https://genomicpress.kglmeridian.com/.

The Genomic Press Interview in Brain Medicine titled "Sara Poletti: From the cradle to the grave," is freely available via Open Access on 10 June 2025 in Brain Medicine at the following hyperlink: https://doi.org/10.61373/bm025k.0071.

About Brain MedicineBrain Medicine (ISSN: 2997-2639, online and 2997-2647, print) is a peer-reviewed medical research journal published by Genomic Press, New York. Brain Medicine is a new home for the cross-disciplinary pathway from innovation in fundamental neuroscience to translational initiatives in brain medicine. The journal's scope includes the underlying science, causes, outcomes, treatments, and societal impact of brain disorders, across all clinical disciplines and their interface.

Visit the Genomic Press Virtual Library: https://issues.genomicpress.com/bookcase/gtvov/

Our full website is at: https://genomicpress.kglmeridian.com/

 

 

Visionary psychedelic researcher reshapes treatment landscape for psychiatric disorders



NYU's Dr. Stephen Ross leads groundbreaking studies using psilocybin therapy for cancer-related distress, addiction, and depression



Genomic Press

Stephen Ross, MD 

image: 

Stephen Ross, MD, New York University School of Medicine, USA.

view more 

Credit: Stephen Ross, MD




NEW YORK, New York, USA, 10 June 2025 – In a comprehensive Genomic Press Interview published today, Dr. Stephen Ross, a leading figure in psychedelic medicine at New York University (NYU), reveals how a serendipitous conversation in 2006 launched his journey into investigating psychedelic compounds as potential breakthrough treatments for some of psychiatry's most challenging conditions.

Rediscovering a forgotten therapeutic approach

"Hidden in plain sight," as Dr. Ross describes it, was an extensive body of research from the 1950s to 1970s involving over 40,000 participants and 1,000 published articles exploring the therapeutic potential of psychedelics. This promising research direction effectively disappeared from psychiatric education and practice following prohibition in 1970.

"Nowhere in my training, ranging from medical school to general psychiatry residency to addiction fellowship training, did I ever hear about this very interesting and significant part of psychiatric history," notes Dr. Ross in the interview. His curiosity about this overlooked research area led to the formation of the NYU Psychedelic Research Group in 2006, helping to spark what he calls "the second wave of psychedelic research."

Breakthrough findings in cancer-related distress

Among Dr. Ross's most significant contributions was a landmark 2016 randomized controlled trial assessing the efficacy of psilocybin-assisted psychotherapy for anxiety, depression, and existential distress in patients with advanced cancer. The study results, which received extensive international coverage and was featured on the front page of the New York Times, demonstrated rapid, substantial, and sustained improvements in psychological symptoms.

"I was shocked at the results of this trial, not expecting such rapid and robust clinical responses," Dr. Ross explains. The treatment not only reduced anxiety and depression but also improved quality of life and reduced existential distress. Approximately 75% of participants rated their psilocybin experience as one of the most meaningful and memorable experiences of their lives.

What makes these findings particularly remarkable? How might these rapid and sustained effects from a single treatment session challenge our current understanding of psychiatric medication, which typically requires daily administration over extended periods?

Expanding therapeutic frontiers

Building on this success, Dr. Ross has expanded his research to include substance use disorders, with promising results from a trial using psilocybin to treat alcohol use disorder, published in JAMA Psychiatry in 2022. This study demonstrated significant reductions in heavy drinking days over an eight-month period following just two doses of psilocybin combined with psychotherapy.

Could psychedelic therapy represent a paradigm shift in addiction treatment, an area where conventional approaches have shown limited effectiveness? What neurobiological mechanisms might explain these sustained effects from limited dosing?

Dr. Ross is also investigating psilocybin's potential in treating major depressive disorder (MDD). As senior author on a phase 2 multi-center trial published in JAMA in 2023, he and colleagues demonstrated that single-dose psilocybin-assisted psychotherapy produced rapid, clinically significant, and sustained reductions in depressive symptoms.

The future of psychedelic medicine

Currently, Dr. Ross is leading an NIH-funded clinical trial, the largest to date, examining psilocybin therapy for cancer-related emotional and spiritual distress. This represents a significant milestone as one of the first NIH grants for psychedelic research in over 50 years. He's also expanding into new therapeutic areas, including fear of recurrence in early-stage breast cancer patients and exploring psychedelics for chronic pain management.

What implications might the mainstreaming of psychedelic therapy have for psychiatric care delivery systems? How might these treatments be integrated into cancer centers, palliative care programs, and addiction treatment facilities if approved?

Dr. Ross's journey hasn't been without obstacles. When he first embarked on psychedelic research, several mentors warned him it was "a road to nowhere" and "a career killer." His persistence in the face of these challenges underscores the potential significance of this therapeutic approach.

Dr. Stephen Ross's Genomic Press interview is part of a larger series called Innovators & Ideas that highlights the people behind today's most influential scientific breakthroughs. Each interview in the series offers a blend of cutting-edge research and personal reflections, providing readers with a comprehensive view of the scientists shaping the future. By combining a focus on professional achievements with personal insights, this interview style invites a richer narrative that both engages and educates readers. This format provides an ideal starting point for profiles that delve into the scientist's impact on the field, while also touching on broader human themes. More information on the research leaders and rising stars featured in our Innovators & Ideas – Genomic Press Interview series can be found in our publications website: https://genomicpress.kglmeridian.com/.

The Genomic Press Interview in Psychedelics titled "Stephen Ross: Psychedelic-assisted therapies for difficult-to-treat psychiatric and medical disorders," is freely available via Open Access on 27 May 2025 in Psychedelics at the following hyperlink: https://doi.org/10.61373/pp025k.0017.

About Psychedelics: Psychedelics: The Journal of Psychedelic and Psychoactive Drug Research (ISSN: 2997-2671, online and 2997-268X, print) is a peer reviewed medical research journal published by Genomic Press, New York. Psychedelics is dedicated to advancing knowledge across the full spectrum of consciousness altering substances, from classical psychedelics to stimulants, cannabinoids, entactogens, dissociatives, plant derived compounds, and novel compounds including drug discovery approaches. Our multidisciplinary approach encompasses molecular mechanisms, therapeutic applications, neuroscientific discoveries, and sociocultural analyses. We welcome diverse methodologies and perspectives from fundamental pharmacology and clinical studies to psychological investigations and societal-historical contexts that enhance our understanding of how these substances interact with human biology, psychology, and society.

Visit the Genomic Press Virtual Library: https://issues.genomicpress.com/bookcase/gtvov/

Our full website is at: https://genomicpress.kglmeridian.com/

 

Cleveland Clinic research finds injectable medications for obesity produce smaller weight loss in a real-world setting, compared to randomized clinical trials



Discontinued treatment, low maintenance dosage led to reduced effectiveness of GLP-1 medications on body weight and blood sugar levels




Cleveland Clinic




 Tuesday, June 10, 2025, 3 a.m. EDT, CLEVELAND: 

A Cleveland Clinic study shows that semaglutide and tirzepatide – injectable GLP-1 drugs for obesity – produce smaller weight loss in a real-world setting because patients discontinue treatment or use lower maintenance dosages. Treatment discontinuation also negatively impacted blood sugar control in patients with prediabetes. The study was published in the Obesity Journal.

Hamlet Gasoyan, Ph.D., lead author of the study and a researcher with Cleveland Clinic’s Center for Value-Based Care Research, said: “Our study shows that patients treated for obesity with semaglutide or trizepatide lost less weight on average in a regular clinical setting compared to what is observed in randomized clinical trials. According to our data, this could be explained by higher rates of discontinuation and lower maintenance dosages used in clinical practice, compared to randomized clinical trial settings.”

Semaglutide (sold under the brand names Wegovy and Ozempic) and tirzepatide (sold under the brand names Zepbound and Mounjaro) are FDA-approved medications for the treatment of type 2 diabetes and chronic weight management. While randomized clinical trials have shown the efficacy of those medications, Dr. Gasoyan and colleagues studied their effect on weight reduction and blood sugar regulation (glycemic control) in a real-world setting.

This Cleveland Clinic retrospective cohort study included 7,881 adult patients with an average body mass index (BMI) greater than 39, which is classified as clinically severe obesity. Among the participants, 1,320 had pre-diabetes at the start of the study, defined by blood sugar levels between 5.7%-6.4%.  Patients who have pre-diabetes are at a higher risk of developing type 2 diabetes, which is one of the most common complications of obesity.

The study participants began treatment for obesity with injectable forms of semaglutide or tirzepatide between 2021 and 2023. Researchers grouped patients who discontinued their obesity medications into those who discontinued early (within 3 months) and late (within 3-12 months). The study’s follow-up ended in December 2024.

Researchers found that more than 20% of patients discontinued their medications early and 32% discontinued their medications late. In addition, more than 80% of study participants were on lower maintenance dosages of those medications (i.e., equal to or less than 1 mg for semaglutide and equal to or less than 7.5 mg for tirzepatide). The maintenance dose refers to the amount of medication needed to sustain a therapeutic effect.

One year after the start of the treatment, researchers found that the average weight reduction was 3.6% among the participants who discontinued their treatment early, compared to 6.8% for those who discontinued their treatment late. Those who did not discontinue treatment lost on average 11.9% body weight. Those who did not discontinue treatment and were on high maintenance dosage of the medications lost 13.7% of their body weight with semaglutide and 18.0% with tirzepatide.

“Our findings about the real-world use patterns of these medications and associated clinical outcomes could inform the decisions of healthcare providers and their patients on the role of treatment discontinuation and maintenance dosage in achieving clinically meaningful weight reductions,” said Dr. Gasoyan.

Researchers also identified what factors were associated with higher odds of achieving weight loss of 10% or more, which provides clinically significant health benefits in this patient population. Patients had higher odds of achieving 10% or greater weight reduction after one year of treatment if they:

  • did not discontinue their medications or discontinued late (vs. early)
  • were on high maintenance dosage
  • received tirzepatide (vs. semaglutide)
  • were female (vs. male).

 

In addition to looking at the factors that affect a person’s weight trajectory, researchers tracked glycemic control in patients who had pre-diabetes at the start of the study.

Among the participants with pre-diabetes, 33% of those who discontinued their treatment early experienced normal blood sugar levels (defined by HbA1c level of 5.6 or lower), compared to 41% who discontinued their treatment late, and 67.9% who did not discontinue treatment.

“In our study, the majority of the patients with pre-diabetes experienced normal blood sugar levels when they continued their treatment,” said Dr. Gasoyan. “Type 2 diabetes is one of the most common complications of obesity, so diabetes prevention is very important. This study highlights that treatment discontinuation, especially early, negatively affects both weight and glycemic control outcomes.”

The most common reasons for discontinuation of treatment included the cost of the medications and insurance coverage–related issues, side effects, and medication shortages. A follow-up study is in the works to quantify why patients discontinue their obesity medications in a real-world setting.

In addition, researchers observed that while patients who discontinued obesity medications lost significantly less weight compared to those who persisted, their weight trajectories remained relatively stable. This will be studied further to identify what additional weight management methods patients are using in real world settings after discontinuation of obesity medications.

 

About Cleveland Clinic

Cleveland Clinic is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education. Located in Cleveland, Ohio, it was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. Cleveland Clinic has pioneered many medical breakthroughs, including coronary artery bypass surgery and the first face transplant in the United States. Cleveland Clinic is consistently recognized in the U.S. and throughout the world for its expertise and care. Among Cleveland Clinic’s 82,600 employees worldwide are more than 5,786 salaried physicians and researchers, and 20,700 registered nurses and advanced practice providers, representing 140 medical specialties and subspecialties. Cleveland Clinic is a 6,728-bed health system that includes a 173-acre main campus near downtown Cleveland, 23 hospitals, 280 outpatient facilities, including locations in northeast Ohio; Florida; Las Vegas, Nevada; Toronto, Canada; Abu Dhabi, UAE; and London, England. In 2024, there were 15.7 million outpatient encounters, 333,000 hospital admissions and observations, and 320,000 surgeries and procedures throughout Cleveland Clinic’s health system. Patients came for treatment from every state and 112 countries. Visit us at clevelandclinic.org. Follow us at x.com/CleClinicNews. News and resources are available at newsroom.clevelandclinic.org.

 

Editor’s Note: Cleveland Clinic News Service is available to provide broadcast-quality interviews and B-roll upon request.